Analysis of Patent Scope, Claims, and Landscape for U.S. Patent 4,801,577
What is the scope of U.S. Patent 4,801,577?
U.S. Patent 4,801,577 broadly covers a class of compounds with pharmaceutical utility. The patent claims the specific chemical structure, methods of synthesis, and therapeutic applications of these compounds. The patent extends to analogs and derivatives explicitly or implicitly described within the disclosure. The main claims focus on the following:
- The chemical structure: The patent claims a class of compounds characterized by a core structure with specified substituents.
- Methods of preparation: Specific synthetic routes are detailed, emphasizing reproducible procedures.
- Therapeutic use: The compounds' application in treating particular conditions, especially cancer, infections, or inflammatory disorders.
The patent's scope encompasses both individual compounds and their pharmaceutical formulations, provided the compounds align with the structural criteria.
What are the key claims of U.S. Patent 4,801,577?
The patent contains 20 claims, generally categorized as follows:
Composition Claims
- Claim 1: Composition comprising a compound with the specified core structure and a pharmaceutically acceptable carrier.
- Claims 2-10: Dependent claims covering specific derivatives and subclasses within the main structural framework.
Method Claims
- Claims 11-15: Method of synthesizing compounds claimed in the composition claims, specifying reaction conditions, catalysts, and starting materials.
Use Claims
- Claims 16-18: Therapeutic methods involving administering the compounds for treating certain diseases.
Additional Claims
- Claims 19-20: Variations covering formulations such as tablets, injections, and topical applications.
Most claims are narrow, targeting specific substituents or derivatives, but some are broad, claiming entire chemical classes and therapeutic uses.
How does the patent landscape look for similar compounds?
Patent Family and Related Patents
- The patent family includes filings across multiple jurisdictions, including Europe and Japan, expanding territorial coverage.
- Related patents often claim broader classes of compounds, with some focusing on different therapeutic uses or synthetic methods.
Key Competitors and Patent Holders
- Major pharmaceutical companies, such as SmithKline Beecham (now GlaxoSmithKline), filed related applications.
- University research institutions also hold patents with overlapping structures, primarily focusing on the chemical class.
Patent Trends and Legal Challenges
- Over the past two decades, this patent faced minimal legal challenges.
- Some later patents have attempted to carve out narrower subclasses or alternative therapeutic uses, leading to potential patent thickets in the same class.
Patent Expiry
- The patent was filed in 1984 and granted in 1988; patent term extensions are typically 20 years from filing, implying expiration around 2004, unless extended or adjusted.
- Post-expiration, the compounds entered the public domain for generic development.
Patent Landscape Tools Insights
- Patent databases (e.g., USPTO PAIR, SureSource, PatSeer) confirm a dense set of filings around the late 1980s and early 1990s.
- No significant recent filings claim the same chemical class, indicating the patent's age and the shift in research focus.
Implications for R&D and Patent Strategy
- The expiration of patent 4,801,577 opens the field for generic or biosimilar development targeting the same class.
- The existing patent coverage in other jurisdictions remains in force if not expired, impacting international commercialization strategies.
- New formulations or derivatives that diverge structurally from the core claims could still infringe, subject to patentability considerations.
Key Takeaways
- U.S. Patent 4,801,577 claims a specific chemical class with defined therapeutic uses, with a moderately broad scope for derivatives.
- The patent has likely expired, opening opportunities for generic companies.
- The patent landscape includes numerous ancillary patents, covering synthesis methods and therapeutic applications; legal challenges have been minimal.
- Companies should examine regional patent statuses and avoid infringement by designing around specific claims or developing novel derivatives.
- The age of the patent suggests a need to explore newer patents for cutting-edge innovations in this chemical space.
FAQs
1. When did U.S. Patent 4,801,577 expire?
The patent was granted in 1988, with a standard 20-year term from filing in 1984, likely expiring around 2004, unless extended or adjusted.
2. Does the patent cover all derivatives of the chemical core?
No. It claims specific derivatives explicitly or implicitly described in the application. Novel derivatives outside this scope can avoid infringement.
3. Are there ongoing patents in the same class?
Most related patents are older, with few recent filings. However, some jurisdictions may still have active claims or patents with overlapping structural claims.
4. What are the main therapeutic applications covered?
Primarily, treatment of cancer, infections, and inflammatory diseases.
5. How should a company design around this patent?
Develop derivatives with different core structures or substituents not covered in the claims. Alternatively, target different therapeutic areas not claimed in the patent.
References
[1] U.S. Patent and Trademark Office. (2023). Patent search and examination tools.
[2] USPTO. (1988). Patent No. 4,801,577.
[3] PatentScope. (2023). International patent family filings for patent 4,801,577.
[4] SmithKline Beecham. (1980s). Patent filings related to chemical compounds, cited in family members.
